Corbus Pharmaceuticals(CRBP) Stock Price Today

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

CRBP Corbus Pharmaceuticals

Watchlist

5.1700
-0.3500-6.34%

Trading Mar 31 15:31 ET

63.24MMarket Cap-1.40P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist Crb-913 for the Treatment of Obesity
ReutersMar 28 08:00 ET
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
Corbus PharmaceuticalsMar 28 00:00 ET
Corbus Pharmaceuticals Holdings Inc. Stock Sheds 4.7%, Underperforms Competitors
Dow JonesMar 19 16:34 ET
After Plunging -22.9% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)
Zacks Mar 19 08:40 ET
Corbus Pharmaceuticals Appoints Ian Hodgson as COO
TipRanksMar 18 16:58 ET
Cannabis Stock Movers For March 18, 2025
BenzingaMar 18 16:30 ET

Comments

Teddy123

Mar 28 20:19

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

$Corbus Pharmaceuticals (CRBP.US)$
Next-Gen Obesity Drug Shows 50x Better Safety Profile Than Previous Treatments as Clinical Trials Begin

Teddy123

Feb 14 20:36

Medical Research analysis

$Corbus Pharmaceuticals (CRBP.US)$
The Phase 1 clinical trial results for CRB-701 represent a significant advancement in the antibody-drug conjugate (ADC) space, particularly in addressing the historical challenges of ADC toxicity profiles. The observed 4% combined rate of peripheral neuropathy across both Western and Chinese studies is notably lower than existing ADC treatments, where rates can exceed 30-50% with current standard-of-care options.
The drug's differentiat...

Teddy123

Feb 14 20:35

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

$Corbus Pharmaceuticals (CRBP.US)$
Breakthrough Cancer Drug CRB-701 Delivers Powerful Results in Phase 1 Trial: Multiple Tumor Types Respond

Teddy123

Feb 11 20:44

Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

$Corbus Pharmaceuticals (CRBP.US)$
Corbus Pharma's Cancer Drug CRB-701 Advances: Key Clinical Data Coming at ASCO-GU - Patient Enrollment Exceeds Targets

Greenx365

Dec 14, 2024 00:06

$Corbus Pharmaceuticals (CRBP.US)$ wtf bought at 18.50 and now 14.9 🥲🥹🙏

CRBP Corbus Pharmaceuticals

Trade Overview

Capital Trend

News

Comments

Market Insights